PRGO · PERRIGO Co plc · Financials
Market Cap
$1.88B
Shares
138.77M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$4.25B
-2.8%
FY2025
Net Income
-$1.43B
-729.7%
FY2025
Gross Margin
35.14%
-0.1pp
FY2025
Operating Margin
-26.39%
-29pp
FY2025
Diluted EPS
-$10.29
-723.2%
FY2025
Operating Cash Flow
$238.5M
-34.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.14B | $4.25B | $4.37B | $4.66B | $4.45B | $4.14B | $4.09B | $3.87B | $4.73B | $4.95B | $5.28B | $4.6B | $4.06B | |
| -$173.1M | — | — | -$173.8M | -$156M | -$125M | -$127.7M | -$117.5M | -$128M | -$168.1M | -$216.6M | -$146M | — | |
| $2.77B | $2.76B | $2.83B | $2.98B | $3B | $2.72B | $2.59B | $2.44B | $2.9B | $2.97B | $3.23B | $2.89B | $2.61B | |
| $1.38B | $1.49B | $1.54B | $1.68B | $1.46B | $1.42B | $1.49B | $1.43B | $1.83B | $1.98B | $2.05B | $1.71B | $1.45B | |
| — | 35.14% | 35.27% | 36.09% | 32.69% | 34.22% | 36.57% | 37.05% | 38.71% | 40.02% | 38.86% | 37.2% | 35.65% | |
| $95M | $95.4M | $112.2M | $122.5M | $123.1M | $122M | $121.7M | $119.2M | $218.6M | $167.7M | $184M | $187.8M | $152.5M | |
| $503M | $526.5M | $546.6M | $641.8M | $584.8M | $536.4M | $545.5M | $538.7M | $595.7M | $598.4M | $665M | $319M | $208.6M | |
| $425.7M | $435.9M | $468M | $522.3M | $512.3M | $482M | $478.5M | $476.5M | $435.9M | $461.1M | $452.2M | $385.2M | $411.3M | |
| $220.3M | $222.7M | $228.5M | $265.8M | $252.4M | $210M | $212.2M | $219.6M | $333.6M | $349.6M | $356.8M | $464.5M | $281M | |
| $350.4M | $337.5M | $325.9M | $359.5M | $338.6M | $312.2M | $384.8M | $396.5M | $423.6M | $444.8M | $457M | $548.8M | $358.9M | |
| $123.3M | $71.9M | $110.1M | $42.2M | $42.5M | $16.9M | $3.2M | $25.9M | $21M | $61M | $31M | $5.1M | $47M | |
| $2.94B | $2.62B | $1.43B | $1.53B | $1.38B | $1.01B | $1.23B | $1.26B | $1.6B | $1.38B | $4.05B | $964.8M | — | |
| -$1.56B | -$1.12B | $112.9M | $151.9M | $78.9M | $410.4M | $265.2M | $174.7M | $236.5M | $598.2M | -$2B | $747.7M | $567M | |
| — | -26.39% | 2.58% | 3.26% | 1.77% | 9.92% | 6.49% | 4.51% | 5% | 12.09% | -37.87% | 16.24% | 13.96% | |
| -$1.21B | -$784.7M | $438.8M | $511.4M | $417.5M | $722.6M | $650M | $571.2M | $660.1M | $1.04B | -$1.54B | $1.3B | $925.9M | |
| $115.5M | -$13.2M | $900K | $10.4M | -$53.1M | -$26.7M | -$16.3M | $68.9M | -$6.1M | $10.1M | -$22.7M | — | -$12.4M | |
| -$34M | — | -$1.5M | -$1.9M | -$1.5M | -$1.1M | — | — | — | $300K | -$4.1M | -$9.9M | $0 | |
| -$1.61B | -$1.3B | -$80.7M | -$8.3M | -$139.1M | $258.7M | — | — | $290.6M | $280.1M | -$4.85B | $248M | $272.6M | |
| $90.7M | $104.4M | $80M | -$3.9M | -$8.2M | $389.6M | -$38.3M | -$10.7M | $159.6M | $160.5M | -$835.5M | $120M | $67.3M | |
| -$1.73B | -$1.43B | -$171.8M | -$12.7M | -$140.6M | -$68.9M | -$162.6M | $146.1M | $131M | $119.6M | -$4.01B | $128M | $205.3M | |
| — | -33.51% | -3.93% | -0.27% | -3.16% | -1.66% | -3.98% | 3.78% | 2.77% | 2.42% | -75.99% | 2.78% | 5.06% | |
| -$1.83B | -$1.26B | -$344.9M | $25M | -$203.1M | -$428.4M | $93M | $200.9M | -$36.5M | $454.5M | -$4.08B | $90.8M | $267.9M | |
| USD/shares | -$12.51 | -$10.29 | -$1.25 | -$0.09 | -$1.04 | -$0.52 | -$1.20 | $1.07 | $0.95 | $0.84 | -$28.01 | $0.92 | $1.78 |
| USD/shares | -$12.52 | -$10.29 | -$1.25G | -$0.09 | -$1.04 | -$0.52G | -$1.19G | $1.07 | $0.95 | $0.84 | -$28.01 | $0.92 | $1.77 |
| shares | — | 138.5M | 137.4M | 135.3M | 134.5M | 133.6M | 136.1M | 136M | 137.8M | 142.3M | 143.3M | 139.3M | 115.1M |
| shares | — | 138.5M | 137.4M | 135.3M | 134.5M | 133.6M | 137.2M | 136.5M | 138.3M | 142.6M | 143.3M | 139.8M | 115.6M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2025: $798.9M in buybacks, $1.36B in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.15×
Peer median 2.46×
EV/EBIT
—
Peer median 17.10×
P/E (TTM)
—
Peer median 15.47×
Peer medians compare against the 46 similar-size Drug Manufacturers - Specialty & Generic companies (of 98 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Consumer Self Care Americas | $2,585,300,000 | $2,693,700,000 | $2,962,300,000 | $2,925,900,000 | $2,693,100,000 | $2,693,000,000 | $2,487,700,000 | $2,411,600,000 |
| Consumer Self Care International | $1,667,700,000 | $1,679,600,000 | $1,693,300,000 | $1,525,700,000 | $1,445,600,000 | $1,395,200,000 | $1,382,200,000 | $1,399,300,000 |
| Other | — | — | — | — | — | — | $0 | $0 |
| RX Pharmaceuticals | — | — | $0 | $0 | $0 | $0 | $0 | $920,800,000 |
| All Other Segments | — | — | — | — | — | — | $0 | $0 |
| Material Reconciling Items | — | — | — | — | — | — | $0 | $0 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $2,540,100,000 | $2,649,300,000 | $2,916,800,000 | $2,870,000,000 | $2,565,900,000 | $2,579,000,000 | $2,360,300,000 | $3,098,300,000 |
| Europe | $1,616,300,000 | $1,604,600,000 | $1,622,500,000 | $1,474,300,000 | $1,393,000,000 | $1,350,600,000 | $1,335,800,000 | $1,347,600,000 |
| Other Geographical Areas | $96,700,000 | $119,500,000 | $116,300,000 | $107,300,000 | $179,800,000 | $158,600,000 | $173,800,000 | $285,800,000 |
| Ireland | $42,100,000 | $39,600,000 | $40,800,000 | $29,300,000 | $23,700,000 | $29,800,000 | $23,400,000 | $25,700,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Contract Manufacturing | $270,900,000 | $306,200,000 | $337,300,000 | $350,100,000 | $299,700,000 | $261,400,000 | $285,300,000 | $300,500,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Consumer Self Care International | -$228,800,000 | $105,000,000 | -$35,200,000 | -$30,000,000 | $36,100,000 | $32,300,000 | $19,600,000 | $6,800,000 |
| Consumer Self Care Americas | -$669,000,000 | $269,900,000 | $389,600,000 | $366,100,000 | $206,500,000 | $465,000,000 | $406,700,000 | $174,400,000 |
| RX Pharmaceuticals | — | — | $0 | $0 | $0 | $0 | $0 | $214,600,000 |
| All Other Segments | — | — | — | — | — | — | $0 | $0 |
| Material Reconciling Items | — | — | — | — | — | — | -$231,400,000 | -$159,300,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Consumer Self Care Americas | -25.9% | 10% | 13.2% | 12.5% | 7.7% | 17.3% | 16.3% | 7.2% |
| Consumer Self Care International | -13.7% | 6.3% | -2.1% | -2% | 2.5% | 2.3% | 1.4% | 0.5% |
| RX Pharmaceuticals | — | — | — | — | — | — | — | 23.3% |
Key facts
CIK
1585364
CUSIP
G97822103
13F (30d)
11 filings
11 filers
Visit website
Investor relations